Develops a botanical synthesis platform to grow plant-based ingredients. Operates in the nutraceuticals and pharmaceuticals segments. Now — the numbers.
The biggest line carries real weight, but it doesn’t decide everything on its own.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 101% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 0.9× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 8% of them.
Analysts' average target sits 170% above today's price.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 85% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 101% a year on average.
Sales run at $34.5M a year. A small number, but proof the product has real buyers.
A loss of $11.1M against $34.5M in annual sales.
At the current pace of spending, the cash lasts about 2.1 years. After that, the company needs to find new money.
On our five-subject report card, BHST sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: BHST is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Analysts’ average target sits above today’s price, yet the valuation grade (8/100) says the stock isn’t cheap.